文献速递肺结节与肺癌

Lung EpiCheck 甲基化血液检测在欧洲和中国高危人群中肺癌检测的验证

Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.
PubMed 文献 · Eur Respir J · 2021-01-14

本研究验证了六标志物甲基化血浆检测 Lung EpiCheck 在欧洲和中国病例对照样本中检测肺癌的性能。欧洲和中国验证集的 AUC 分别为 0.882 和 0.899,在低 Cut-off 下敏感性/特异性分别为 87.2%/64.2% 和 76.7%/93.3%,在高 Cut-off 下分别为 74.3%/90.5% 和 56.7%/100.0%。结论认为该检测在预测肺癌方面表现强劲,能检测出高比例的早期 NSCLC 和 SCLC,但需前瞻性研究确认。

要点

  • Lung EpiCheck 是一种六标志物甲基化血浆检测,用于肺癌检测。
  • 欧洲和中国验证集 AUC 分别为 0.882 和 0.899。
  • 欧洲验证集中,该检测预测肺癌的能力独立于年龄、吸烟、COPD 等既定风险因素。

核心结论

  • Lung EpiCheck 在欧洲和中国病例对照样本中展现出较强的肺癌预测性能,能检测出高比例的早期 NSCLC 和 SCLC,并显著提高既定风险因素的预测准确性。
  • 需要前瞻性研究来确认这些发现。

研究设计与样本

  • 欧洲训练集为病例对照设计,包括 102 例肺癌病例和 265 例对照,用于确定标志物组合和算法。
  • 在欧洲和中国验证集中评估性能,病例/对照分别为 179/137 和 30/15。
  • 选择两个 Cut-off:低 Cut-off 用于高敏感性,高 Cut-off 用于高特异性。

主要发现

  • 欧洲和中国验证集的 AUC 分别为 0.882 和 0.899。
  • 低 Cut-off 下,欧洲和中国验证集的敏感性/特异性分别为 87.2%/64.2% 和 76.7%/93.3%。
  • 高 Cut-off 下,欧洲和中国验证集的敏感性/特异性分别为 74.3%/90.5% 和 56.7%/100.0%。
  • 欧洲和中国样本中,低 Cut-off 下 I 期 NSCLC 敏感性分别为 78.4% 和 70.0%,高 Cut-off 下分别为 62.2% 和 30.0%。
  • SCLC 仅在欧洲集中有代表,低 Cut-off 和高 Cut-off 下敏感性分别为 100.0% 和 93.3%。

关键数值与推荐

  • 欧洲验证集多变量分析中,该检测预测肺癌的能力独立于年龄、吸烟、COPD 等既定风险因素,总体 AUC 为 0.942。

临床怎么用

  • 使用简单且廉价的血液检测可能提高依从性并扩大高危人群的筛查可及性。

局限性

  • 研究为病例对照设计,需要前瞻性研究确认 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Lung cancer screening reduces mortality. We aim to validate the performance of Lung EpiCheck, a six-marker panel methylation-based plasma test, in the detection of lung cancer in European and Chinese samples. METHODS: A case-control European training set (n=102 lung cancer cases, n=265 controls) was used to define the panel and algorithm. Two cut-offs were selected, low cut-off (LCO) for high sensitivity and high cut-off (HCO) for high specificity. The performance was validated in case-control European and Chinese validation sets (cases/controls 179/137 and 30/15, respectively). RESULTS: The European and Chinese validation sets achieved AUCs of 0.882 and 0.899, respectively. The sensitivities/specificities with LCO were 87.2%/64.2% and 76.7%/93.3%, and with HCO they were 74.3%/90.5% and 56.7%/100.0%, respectively. Stage I nonsmall cell lung cancer (NSCLC) sensitivity in European and Chinese samples with LCO was 78.4% and 70.0% and with HCO was 62.2% and 30.0%, respectively. Small cell lung cancer (SCLC) was represented only in the European set and sensitivities with LCO and HCO were 100.0% and 93.3%, respectively. In multivariable analyses of the European validation set, the assay's ability to predict lung cancer was independent of established risk factors (age, smoking, COPD), and overall AUC was 0.942. CONCLUSIONS: Lung EpiCheck demonstrated strong performance in lung cancer prediction in case-control European and Chinese samples, detecting high proportions of early-stage NSCLC and SCLC and significantly improving predictive accuracy when added to established risk factors. Prospective studies are required to confirm these findings. Utilising such a simple and inexpensive blood test has the potential to improve compliance and broaden access to screening for at-risk populations.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Gaga M, Chorostowska-Wynimko J, Horváth I, et al. Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals. Eur Respir J. 2021. PMID: 33122336. doi:10.1183/13993003.02682-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。